StreetInsider.com News Articles

William Blair Starts Zura Bio Ltd. (ZURA) at Outperform

Wed, 08 Jul 2026 04:51:23 -0400

William Blair analyst Matt Phipps initiates coverage on Zura Bio Ltd. (NASDAQ: ZURA) with a Outperform rating.

The analyst comments "We are initiating coverage of Zura Bio based on the potential of the dual mechanism of action with the bispecific tibulizumab to drive differentiated efficacy in two ongoing Phase II studies in hidradenitis suppurativa (HS) and systemic sclerosis (SSc). As outlined in this report, we believe there is significant translational data to support the role of both B cells and T cells in driving immunopathogenesis and inflammation in many autoimmune diseases, particularly HS and SSc. By inhibiting both BAFF and IL-17,

William Blair Starts Zura Bio Ltd. (ZURA) at Outperform

Wed, 08 Jul 2026 04:51:23 -0400

William Blair analyst Matt Phipps initiates coverage on Zura Bio Ltd. (NASDAQ: ZURA) with a Outperform rating.

Zura Bio exceeds enrollment targets in two Phase 2 drug trials

Mon, 29 Jun 2026 07:30:42 -0400

Zura Bio Limited (Nasdaq: ZURA) announced that its Phase 2 TibuSHIELD trial of tibulizumab in adults with hidradenitis suppurativa (HS) has completed enrollment with 247 participants, exceeding its original target. The company also said its TibuSURE trial in adults with early diffuse cutaneous systemic sclerosis (SSc) has surpassed its 80-participant enrollment target and remains on track to complete enrollment in early July.

Topline data from TibuSHIELD are expected in the fourth quarter of 2026, while topline data from TibuSURE are expected in the first half of 2027.

Tibulizumab is a bispecific antibody targeting both IL-17 and BAFF pathways. Zura said it plans

Zura Bio exceeds enrollment targets in two Phase 2 drug trials

Mon, 29 Jun 2026 07:30:42 -0400

Topline data from TibuSHIELD are expected in the fourth quarter of 2026, while topline data from TibuSURE are expected in the first half of 2027.

Tibulizumab is a bispecific antibody targeting both IL-17 and BAFF pathways. Zura said it plans

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

Mon, 29 Jun 2026 07:30:00 -0400

Tibulizumab is the first and only bispecific antibody targeting both BAFF and IL-17 in clinical development
TibuSHIELD has completed enrollment, exceeding enrollment target with 247 participants randomized in HS; topline data expected Q4 2026
TibuSURE has exceeded the 80 participant enrollment target in SSc and remains on track to complete enrollment in early July; topline data expected H1 2027
Zura plans to initiate a Phase 2 study for tibulizumab in a third immune-mediated indication by year end 2026

HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical stage biotechnology company developing novel and differentiated

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

Mon, 29 Jun 2026 07:30:00 -0400

Tibulizumab is the first and only bispecific antibody targeting both BAFF and IL-17 in clinical development
TibuSHIELD has completed enrollment, exceeding enrollment target with 247 participants randomized in HS; topline data expected Q4 2026
TibuSURE has exceeded the 80 participant enrollment target in SSc and remains on track to complete enrollment in early July; topline data expected H1 2027
Zura plans to initiate a Phase 2 study for tibulizumab in a third immune-mediated indication by year end 2026

HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical stage biotechnology company developing novel and differentiated

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

Mon, 29 Jun 2026 07:30:00 -0400

Tibulizumab is the first and only bispecific antibody targeting both BAFF and IL-17 in clinical development
TibuSHIELD has completed enrollment, exceeding enrollment target with 247 participants randomized in HS; topline data expected Q4 2026
TibuSURE has exceeded the 80 participant enrollment target in SSc and remains on track to complete enrollment in early July; topline data expected H1 2027
Zura plans to initiate a Phase 2 study for tibulizumab in a third immune-mediated indication by year end 2026

HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical stage biotechnology company developing novel and differentiated

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

Mon, 29 Jun 2026 07:30:00 -0400

Tibulizumab is the first and only bispecific antibody targeting both BAFF and IL-17 in clinical development
TibuSHIELD has completed enrollment, exceeding enrollment target with 247 participants randomized in HS; topline data expected Q4 2026
TibuSURE has exceeded the 80 participant enrollment target in SSc and remains on track to complete enrollment in early July; topline data expected H1 2027
Zura plans to initiate a Phase 2 study for tibulizumab in a third immune-mediated indication by year end 2026

HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical stage biotechnology company developing novel and differentiated

Form 3 Zura Bio Ltd For: Apr 17 Filed by: Mathew Marlyn Teresa

Mon, 22 Jun 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260622/26673903.html

Form 3 Zura Bio Ltd For: Apr 17 Filed by: Mathew Marlyn Teresa

Mon, 22 Jun 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260622/26673903.html

Form 4 Zura Bio Ltd For: Jun 17 Filed by: Thiara Parvinder

Mon, 22 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260622/26673288.html

Form 4 Zura Bio Ltd For: Jun 17 Filed by: Thiara Parvinder

Mon, 22 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260622/26673288.html

Form 4 Zura Bio Ltd For: Jun 17 Filed by: Jarrett Jennifer

Mon, 22 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260622/26673303.html

Form 4 Zura Bio Ltd For: Jun 17 Filed by: Jarrett Jennifer

Mon, 22 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260622/26673303.html

Form 4 Zura Bio Ltd For: Jun 17 Filed by: Munshi Amit